Clinical trial NCT00046072: A Safety and Efficacy Study of Intravenous E5564 in Patients With Severe Sepsis
Official title: A Double-Blind, Placebo-Controlled Study of E5564, A Lipid A Antagonist, Administered by Twice Daily Infusions in Patients With Severe Sepsis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Sepsis
Shock, Septic
Sepsis Syndrome
Septicemia
Infection
Keywords: Sepsis
Shock
Septic
Sepsis Syndrome
Septicemia
Endotoxins
Endotoxemia
Infection
Lead sponsor: Eisai Inc.
Sponsor class: INDUSTRY
First posted: 2002-09-20
Enrollment: 300
Sex: ALL
Minimum age (years): 18
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Sepsis is a serious condition where there is inflammation and damage to body tissue, usually caused by an infection. This infection can lead to decreased function of vital body organs and in some cases may lead to permanent health problems or death.

Much of the injury is due to endotoxin, a harmful substance produced by certain types of bacteria. An endotoxin antagonist is designed to block the effects of endotoxin.

This study is designed to study the safety and efficacy when treating patients with severe sepsis.


Eligibility criteria: Inclusion Criteria:

* Presently admitted, or about to be transferred, to the ICU.
* Women of Child-bearing potential must have a negative serum (or urine) hCG assay within 24 hours prior to drug administration.
* Any Race.
* Severe Sepsis \[newly developed respiratory failure, refractory shock, renal dysfunction, hepatic dysfunction, or metabolic acidosis and at least three signs of SIRS (systematic inflammatory response syndrome)\].
* Objective signs of infection likely to be caused by a bacterial or fungal pathogen.
* Patients must receive study medication within 8 to 12 hours of recognition of the initial sepsis-related organ failure.
* APACHE Predicted risk of mortality score between 20% and 80%.
* An intent by physicians and family to aggressively treat the patient for the 28 day study period.

Exclusion Criteria:

* Cardiogenic or hypovolemic shock.
* Acute third degree burns involving \>20% of body surface.
* Recipients of non-autologous organ transplants within the past year.
* Pregnancy.
* Chronic vegetative state.
* Uncontrolled serious hemorrhage (.2 units of blood/platelets in the previous 24 hours). Patients may be considered for enrollment if bleeding has stopped and patients are still otherwise qualified.
* Unwilling or unable to be fully evaluated for all follow-up visits.
* Patients who are classified as "Do not resusitate" or "Do not treat."
* Patients who develop severe sepsis \<36 hours post trauma or post-surgery. Patients may be considered for enrollment \>36 hours post-trauma or post-surgery, if they meet other inclusion criteria.
* Patients with a predicted risk of mortality score of \<20% or \>80% after recognition of qualifying organ failure.
* Patients with a predicted risk of mortality of \<51% for whom Xigris® use is planned.

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Mobile
country: United States
state: Alabama
city: San Diego
country: United States
state: California
city: Santa Barbara
country: United States
state: California
city: Jacksonville
country: United States
state: Florida
city: Miami
country: United States
state: Florida
city: Pensacola
country: United States
state: Florida
city: Columbus
country: United States
state: Georgia
city: Elk Grove
country: United States
state: Illinois
city: Kansas City
country: United States
state: Kansas
city: Boston
country: United States
state: Massachusetts
city: Springfield
country: United States
state: Massachusetts
city: Buffalo
country: United States
state: New York
city: Manhasset
country: United States
state: New York
city: Oklahoma City
country: United States
state: Oklahoma
city: Dallas
country: United States
state: Texas
city: Galveston
country: United States
state: Texas
city: San Antonio
country: United States
state: Texas
Study officials:
affiliation: Eisai Inc.
name: Alec Wittek, M.D.
role: STUDY_DIRECTOR
References: